Close Menu

Immunotherapy

News and reporting on cancer immunotherapy.

The project is collaborating with nine biopharma companies to combine more real-world clinical data with genomic data.

The researchers identified specific macrophage and conventional dendritic cell subsets as key mediators of cellular crosstalk in the tumor microenvironment.

A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.

Two recent acquisitions have resulted in the swift launch of two assays, one for the clinic and another for research use, as the firm's original test finally nears validation.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

In PNAS this week: immune gene expression differences in blood of young adults, molecular contributors to cells' microtubule and actin networks, and more.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

Extending a prior agreement with the drugmaker, Personalis will use its DNA/RNA platform to identify both predictive biomarkers and resistance mechanisms.

In Science this week: phase I study of CRISPR-based engineering of T cells for cancer patients, call for sewage-based global antimicrobial resistance surveillance system, and more.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.